Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 12/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR1F | P30939 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429643 | 0.83 | HTR1D (0.50) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL23264399 | 0.79 | ALDH1A1 (0.51) | SCDALDH1A1GRIA2NOS1 | |
| SCHEMBL13537238 | 0.79 | HTR1F (0.62) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL2675996 | 0.78 | OPRM1 (0.62) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL14208735 | 0.78 | HTR1D (0.46) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL429286 | 0.77 | HTR1A (0.48) | HTR1AHTR1DHTR1BHTR1FALDH1A1 | |
| SCHEMBL5255129 | 0.77 | TP53 (0.53) | — | |
| SCHEMBL428109 | 0.76 | CHRM2 (0.40) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL2625792 | 0.73 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL2675961 | 0.73 | NOS1 (0.48) | SCDHTR1AHTR1DHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | SCD 980/4885HTR1A 691/4885HTR1D 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.